Submit Deal

Announced

11 Dec 2024

Completed

11 Dec 2024

EQT Life Sciences led a CHF27m Series B extension in Noema Pharma.

Synopsis

EQT Life Sciences led a CHF27m Series B extension in Noema Pharma, a clinical-stage biotech company. With its investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.

Principals

target

Noema Pharma

bidder

Eqt Life Sciences

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (10)

ilise lombardo

CEO at NOEMA PHARMA

Manager

target

Deal

£ 24 M

Total Value

hana malik

Account Director at Optimum Strategic Communications

PR Consultant

target

Deals

£ 58 M

Total Value

anne rein

Director at StrategiesImage

PR Consultant

target

Deals

£ 3.34 B

Total Value

andreas müller

Partner at Homburger

Lawyer

target

Deals

£ 32.25 B

Total Value

thierry burckhardt

Associate at Homburger

Lawyer

target

Deals

£ 14.61 B

Total Value

thomas romelli

Associate at Homburger

Lawyer

target

Deals

£ 344 M

Total Value

thomas sigrist

Junior Associate at Homburger

Lawyer

target

Deal

£ 24 M

Total Value

luca dal molin

Partner at Homburger

Lawyer

target

Deals

£ 30.13 B

Total Value

stefan oesterhelt

Partner at Homburger

Lawyer

target

Deals

£ 61.85 B

Total Value

$laetitia fracheboud$

laetitia fracheboud

Associate at Homburger

Lawyer

target

Deals

£ 33.70 B

Total Value

Bidder Team (1)

felice verduyn-van weegen

Partner at EQT LIFE SCIENCES

Manager

bidder

Deals

£ 926 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy